TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of FiO2 and ORi value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Correlation of PaO2 and ORi value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cytokines and other markers of Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutrophil redistribution and phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Hepatitis B Virus Surface Antigen Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of change of intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in thrombotic burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Objective Response (OR)
Endpoint domain: Adverse events/effects
Primary endpoint: Flurbiprofen plasma and capillary rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Metabolic Flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of Tremor Severity Following Transcutaneous Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Range of motion of the shoulders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to first successful extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Negative nutritional outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to reach the maximum plasma concentration of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vasoreactivity During Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Concussion Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sensory and motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in General Paranoid Ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Social Paranoia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incisional Hernia
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) and/or Recommended dose (RD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intestinal microbiota (composition, abundance, and diversity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of early stage lung cancer/precancerous lesions detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity for Detection of Full Extent of Malignant Breast Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Breast Level Specificity of CMRM for Non-malignant Breasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With a Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Weight-for-Length Z Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIV outcome prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline Y-GTSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pelvic floor muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Intensity of Abdominal Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Response of no Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological assessment of transpedicular screws
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in vitamin D blood level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MOD Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mitochondrial DNA methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Complete or Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist Circumference in Centimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best overall response rate (PR plus CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Cue-induced Cravings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Joint Position Matching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional anisotropy (FA) measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Radial diffusivity (RD) measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean diffusivity (MD) measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Axial diffusivity (AD) measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression Free Survival Rate at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Number of transfused red blood cell (RBC) units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Length of Bonding Appointment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Debonded Brackets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Current Opioid Misuse Measure (COMM)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in carboxy-terminal collagen crosslinks (CTX) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma sodium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recruitment Rate of patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Optimal BP and lipid control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participants With Withdrawal-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects experiencing dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of adverse events (AEs) and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of response (time from first response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Achieving Hemoglobin A1C <7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: At Least 1 TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute Change in Fasting Triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pulse wave amplitude (PWA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change From Baseline in BCVA Letter Score at Week 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Week 12 in BCVA Letter Score at Week 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Aesthetic Improvement of the Buttocks Using Investigator GAIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Improvement in Cellulite Severity Compared to Baseline Using the Cellulite Severity Scale (CSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of CSS Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with novel mutations in sodium channel genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Feasibility of completing clinical and laboratory protocols
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to mental health services (yes/no response for 4-week period)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to mental health services (total # of sessions for 4-week period)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to mental health services (yes/no response for 6-month period)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to mental health services (total # of sessions for 6-month period)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Any Device-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in NPC Disease Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Relative risk of NVAF patients for ischemic stroke after OAC discontinuation
Endpoint domain: Mortality/survival
Primary endpoint: Hypothermia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Touch evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal allergen challenge response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specificity for Lung Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Forearm perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Influenza Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CMR-derived microvascular obstruction (MVO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to reach maximum (peak) plasma concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of romiplostim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Need for Additional Uterotonics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participation to colorectal cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Successful discontinuation of immunosuppressive therapy (IS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of normal allograft status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Pain Intensity of 30% or More
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at EOS Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at EOT Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prandial blood glucose lowering profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline sequential finger tapping performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline oxygenated haemoglobin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline shape-counting error
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intracoronary ischemia change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disabilities of the Arm, Shoulder, and Hand Survey (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: incisional herniation
Endpoint domain: Adverse events/effects
Primary endpoint: Endothelial Cell Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: treatment success rate of aortic dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of no major adverse events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Short-form McGill pain questionnaire (SF-MPQ)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Days to engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and severity of infusion-associated events
Endpoint domain: Adverse events/effects
Primary endpoint: Overall number and frequency of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first recurrence of AF, atrial flutter, or left atrial tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of days with moderate or severe influenza-like symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal pocket depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venous blood lead
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of ReSTE Imaging in Diagnosis of Ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Healing at 6-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in psychological insulin resistance at 2 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in psychological insulin resistance at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in psychological insulin resistance at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum erythropoietin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intraocular Pressure in the Study Eye at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Number of Headache Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to Use the Study Regimen and Remain on PrEP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Adolescents Who Continue to Use PrEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grades 2, 3, and 4 Clinical and Laboratory Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Nicotine craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic tolerance of segmental spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Respiratory safety of segmental spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative atrial fibrillation development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: success of estimation of the correct vertebral space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in migraine headache pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SSEP response to positive touch stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of falls
Endpoint domain: Adverse events/effects
Primary endpoint: Number of New HIV Diagnosed Prior to Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of PLWH Identified in First 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Entrants with Acute HIV Infection Identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient's experience of acu-stimulation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Follow-Up Completion Rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to Complete Intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Systemic Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Average pain intensity over one year post-randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average disability over one year post-randomization
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevention of chronic low back pain (LBP) that is impactful at 10-12 months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with tropic ulcers cured
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ki values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Oncological Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Retention Rate (Linkage to Care)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: quality of life trend
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: % platelet inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum bone turnover markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Functional Assessment of the Cancer Therapy scale (FACT-G and FACT H&N)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Glucose biomarker data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of previously unrecognized MPS I, II, IVA, and VI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of sit-to-stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in LDL-C From Baseline To Day 510
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 540
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: overall and event free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in the number of women screened for the first time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: working memory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fpulmonary
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Who Were Week 8 Responders With Durable Clinical Response at Week 56
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative dose intensity (RDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of moderate and severe chemotherapy-associated toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of Urine Albumin to Creatinine Ratio (ACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pharyngeal Swallow Trigger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laryngeal Penetration, Mild
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracheal Aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in testicular size estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Exercise endurance exhaustion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ammonia level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CK level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Stay (LOS) duration in days
Endpoint domain: Resource use
Endpoint subdomain: Hospital